Shoulder Innovations stock
SINYSEShoulder Innovations, Inc., HealthcareISIN US82537J1088
48Score 48 out of 100, Weak
Price and trend
87 / 100
Price history
+41% in one yearThe chart shows daily closes over 1 year, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 22% above it.
Normal: the price is neither overheated nor sold off (RSI 59).
The price is 13% below its 52-week high. Largest decline in 1 year: 31% (September 2025 to November 2025).
Chart figures for advanced users
- SMA 50$19.06
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$17.30
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)59
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$12.25
- The lowest closing price of the last twelve months.
- Resistance$24.25
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Shoulder Innovations, Inc. belongs to the Medical (Specialties) industry (United States) and, with a market value of $441.04M, is number 10 of 14 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $47.32M (up 49.6% year on year) and a loss of $40.36M.
- For fiscal 2026, analysts expect on average revenue of $67.97M (up 43.7%) and adjusted earnings per share of −$1.85.
Show more
- MEQIRI Score 48 out of 100 (Weak): rank 411 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $92.33M, financial debt $14.89M.Stability 53
Weaknesses
- Loss-makingLoss of $33.35M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$42.69M over the last 12 months.Fundamentals 17
- Volatile share priceVolatility 68% a year over the last 12 months.Stability 53
Its standout strengths are momentum and technical analysis, while profitability and fundamentals hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
No fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 54.9% on the twelve months before. Revenue has grown strongly since 2023, at around 57% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 77%, operating −56%, net −85%. Last 12 months: net −52%.
Debt & balance sheet
latest quarterDebt is low, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 9 Mar 2027in 117 days
- Last reported
- 5 Nov 2026EPS reported −$0.34 (expected −$0.49)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$1.850.0%
- Revenue
- $67.97M0.0%
- Earnings per share
- −$1.570.0%
- Revenue
- $87M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +16.6%2026 net revenue guidance raised to $65 million to $68 million, growth of 37% to 44% over 2025.
“And as a result, we are raising our full year 2026 net revenue guidance today to a range of $65 million to $68 million, representing growth of 37% to 44% over 2025. This compares to our prior range of $62 million to $65 million or 31% to 37% growth.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 13 May 2026 (fiscal Q1 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 3 insiders sold, $5.47M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Ball Robert JosephSale
14 Sept 2026, CEO & Executive Chairman
- Shares
- 10,175
- Price
- $18.45
- Value
- $187,706
- Gilde Healthcare Holding B.V.Sale
26 Aug 2026, Major holder
- Shares
- 1,196
- Price
- $22.60
- Value
- $27,030
- Gilde Healthcare Holding B.V.Sale
24 Aug 2026, Major holder
- Shares
- 681
- Price
- $22.62
- Value
- $15,404
Show 12 more
- Gilde Healthcare Holding B.V.Sale
21 Aug 2026, Major holder
- Shares
- 20,516
- Price
- $22.61
- Value
- $463,867
- Gilde Healthcare Holding B.V.Sale
20 Aug 2026, Major holder
- Shares
- 3,900
- Price
- $22.60
- Value
- $88,140
- Ahearn Matthew FraserSale
18 Aug 2026, Chief Operating Officer
- Shares
- 14,186
- Price
- $20.99
- Value
- $297,704
- Ahearn Matthew FraserSale
17 Aug 2026, Chief Operating Officer
- Shares
- 8,314
- Price
- $20.10
- Value
- $167,101
- Gilde Healthcare Holding B.V.Sale
6 Aug 2026, Major holder
- Shares
- 2,095
- Price
- $22.60
- Value
- $47,347
- Gilde Healthcare Holding B.V.Sale
5 Aug 2026, Major holder
- Shares
- 7,338
- Price
- $22.64
- Value
- $166,132
- Gilde Healthcare Holding B.V.Sale
4 Aug 2026, Major holder
- Shares
- 99,812
- Price
- $22.77
- Value
- $2.27M
- Gilde Healthcare Holding B.V.Sale
3 Aug 2026, Major holder
- Shares
- 10,751
- Price
- $22.71
- Value
- $244,155
- Gilde Healthcare Holding B.V.Sale
31 Jul 2026, Major holder
- Shares
- 20,034
- Price
- $22.73
- Value
- $455,373
- Gilde Healthcare Holding B.V.Sale
30 Jul 2026, Major holder
- Shares
- 28,245
- Price
- $23.36
- Value
- $659,803
- Ahearn Matthew FraserSale
15 Jun 2026, Chief Operating Officer
- Shares
- 4,144
- Price
- $18.84
- Value
- $78,070
- Ahearn Matthew FraserSale
12 Jun 2026, Chief Operating Officer
- Shares
- 15,856
- Price
- $18.68
- Value
- $296,185
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Shoulder Innovations
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 48
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Specialties)
The next larger and next smaller companies by market value
- Medacta GroupMOVE.SW $2.64B58
- Eckert & ZieglerEUZ.DE $969.93M74
- QuidelOrthoQDEL $817.18M32
- Mesa LaboratoriesMLAB $782.43M58
- Mobia MedicalMOBI $448.43M45
- BrainsWayBWAY $440.87M60
- 908 DevicesMASS $415.82M43
- IVF Hartmann HoldingVBSN.SW $357.26M69
ETFs that hold Shoulder Innovations
Held by 2 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.01% | 0.30% | €2.17B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.00% | 0.30% | €4.22B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Jul 2026)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.